# R-Biopharm

R-Biopharm is a Corporate Investor based in Darmstadt, Germany.

## Overview

- **Organization type:** Corporate Investor
- **Headquarters:** Darmstadt, Germany
- **Region:** Europe
- **Address:** An der neuen Bergstraße 17, 64297 Darmstadt, Germany
- **Founded:** 1988
- **Assets under management:** Undisclosed
- **Website:** www.r-biopharm.com
- **LinkedIn:** https://www.linkedin.com/company/r-biopharm-corporate
- **Wikidata:** Q50639110

## Regulatory record

- **Reports private funds:** No

## About

R-Biopharm was carved out of Röhm GmbH in 1988 and taken private by Dr. Ralf M. Dreher via a management buyout in 1991. The Dreher family controls the Darmstadt-based group through HRT Beteiligungs GmbH & Co. KG, having bought out minority shareholder BWK GmbH in 2022. The firm unites R&D, production, and distribution at its headquarters, with 29 subsidiaries and 120 distributors spanning the US, UK, France, Italy, China, India, and Brazil. Capital is deployed as a corporate investor backing early-stage diagnostic and life-science tools startups that complement its core portfolio. Core commercial franchises include clinical IVD kits, food and feed allergen testing systems — where the company claims global market leadership in allergen analysis — and a nutrition care unit pairing diagnostics with individualized wellness programs. R-Biopharm reached a landmark in June 2022 when it gained IVDR 2017/746 certification, while its 2022 acquisition of Sydney-based AusDiagnostics added proprietary multiplex molecular biology platforms to the group's consolidated "Made in Germany" manufacturing backbone. The group employs more than 1,400 people worldwide and operates from a purpose-built Darmstadt campus with additional real-estate holdings in Bensheim and Pfungstadt. R-Biopharm Inc., its US subsidiary in Washington, Missouri, provides American distribution. Dr. Ralf Dreher handed the chairmanship to Christian Dreher in 2018 as part of a deliberate family succession. June 2022 brought two milestones: the AusDiagnostics acquisition and full IVDR certification. Philanthropic activities are organized under the Waldoni Kinder- und Jugendstiftung foundation. The firm differentiates through vertical integration rarely seen among mid-market biotech peers. By keeping research, development, and production under one roof, R-Biopharm shortens the feedback loop between in-house manufacturing and regulatory cycles — a structural advantage when competing against larger CRO-dependent platforms. This architecture allows the Dreher family to reinvest free cash flow into bolt-on acquisitions and early-stage corporate venture deals without external LP constraints.

## Sectors

- Healthcare Services
- Diagnostics & Life Sciences Tools

## Offices

- Washington, MO, United States
- Pfungstadt, Germany
- Bensheim, Germany

## People

- Christian Dreher — CEO
- Dr. Ralf M. Dreher — Founder

## Questions

### Who owns R-Biopharm?

The Dreher family controls R-Biopharm through HRT Beteiligungs GmbH & Co. KG. Founder Dr. Ralf M. Dreher acquired the business from Röhm GmbH in a 1991 management buyout and later bought out the minority shareholder BWK GmbH in 2022, making it fully family-owned. Christian Dreher, son of the founder, has been CEO since 2018.

### What is R-Biopharm's corporate venture strategy?

R-Biopharm operates as a corporate investor, allocating operating-company cash flows to early-stage biotechnology and diagnostic-tool startups aligned with its core clinical and food-analysis portfolio. The firm targets deals that extend its vertical-integration model, favoring technologies that can be scaled through its own manufacturing and distribution infrastructure.

### Does R-Biopharm have a private equity or external LP arm?

No. R-Biopharm's investment activity is funded entirely from its balance sheet and operating cash flows. It does not manage external limited-partner capital or operate a separate venture-capital vehicle, which distinguishes it from many healthcare-focused institutional investors.

### Which sectors does R-Biopharm explicitly avoid?

The firm's entire disclosed footprint — from commercial kits to corporate venture bets — stays within clinical diagnostics, food and feed analysis, and nutrition care. It has no known presence in therapeutics, drug discovery, agricultural biotechnology outside the food-safety chain, or pure-play health-tech software.

### How is R-Biopharm's philanthropy structured?

Philanthropic activities are housed in the Waldoni Kinder- und Jugendstiftung, a foundation focused on children and youth. Governance is kept separate from the commercial group, maintaining a clear boundary between charitable disbursements and the balance sheet used for corporate venture investments.

## Related profiles

- [RBG Partners](https://altss.com/profile/rbg-partners)
- [RBK Holding](https://altss.com/profile/rbk-holding)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/r-biopharm

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology